TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9537731

Group type: EXPERIMENTAL
Intervention: Gauze drain impregnated with chlortetracycline ointment
Number of subjects: 26

Group type: COMPARATOR
Intervention: No drain treatment (control)
Number of subjects: 26
Study: 8079448

Group type: EXPERIMENTAL
Intervention: Low-dose IVIgG (85.7 +/- 11.6 mg/kg by ultrasound‐estimated fetal weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrauterine intravascular red cell transfusions (IUT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose IVIgG
Number of subjects: 20
Study: 2590616

Group type: EXPERIMENTAL
Intervention: Intranasal metoclopramide (5 mg in 0.5 ml sterile water)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral route (implied control)
Number of subjects: 0
Study: 241307

Group type: EXPERIMENTAL
Intervention: Single daily administration of phenothiazine medication
Number of subjects: 24

Group type: COMPARATOR
Intervention: Multiple administration schedule of phenothiazine medication
Number of subjects: 24
Study: 31711880

Group type: EXPERIMENTAL
Intervention: Active high-frequency DMPFC-rTMS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Active low-frequency DMPFC-rTMS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham DMPFC-rTMS
Number of subjects: 120
Study: 31329855

Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 90 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 15 mg weekly for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 30 mg weekly for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 60 mg every 4 weeks for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx
Number of subjects: 0
Study: 28038840

Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 409
Study: 26171911

Group type: EXPERIMENTAL
Intervention: Trebananib (15mg/kg, IV QW)
Number of subjects: 32
Study: 24029303

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (exercise training, salt restriction, nutrition advice) for 24 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 21159452

Group type: EXPERIMENTAL
Intervention: MMT with weekly individual BDRC (n=20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard MMT (n=17)
Number of subjects: 37
Study: 18193489

Group type: EXPERIMENTAL
Intervention: Magnesium carbonate (MgCO(3))
Number of subjects: 46

Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO(3))
Number of subjects: 46
Study: 16640847

Group type: EXPERIMENTAL
Intervention: DTPw-HB/Hib vaccine (5 microg of PRP), given as a single injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed DTPw-HB (Tritanrix) and Hib (Hiberix) vaccines, given as simultaneous concomitant injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTPw-HB/Hib vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed DTPw-HB and Hib vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccination regimens
Number of subjects: 0
Study: 12969103

Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam (1 mg) added to 3 ml of 0.5% hyperbaric bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (3 ml of 0.5% hyperbaric bupivacaine alone
Number of subjects: 40
Study: 10718796

Group type: EXPERIMENTAL
Intervention: Total fundoplication
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Calibration of the cardia with posterior gastropexy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Barrett's oesophagus
Number of subjects: 164

Group type: COMPARATOR
Intervention: Visick I or II
Number of subjects: 164
Study: 8808360

Group type: EXPERIMENTAL
Intervention: Discharge instructions with the modular, multidisciplinary pediatric burn discharge book
Number of subjects: 123

Group type: COMPARATOR
Intervention: Routine discharge teaching without the book
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Discharge instructions with the modular, multidisciplinary pediatric burn discharge book (NAI families)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Routine teaching (NAI families)
Number of subjects: 123
Study: 1345260

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg o.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-measurements of blood pressure (self-BP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Office blood pressure (office-BP)
Number of subjects: 0
Study: 3974160

Group type: EXPERIMENTAL
Intervention: Pindolol eye drops 1%
Number of subjects: 33

Group type: COMPARATOR
Intervention: Timolol eye drops 0.5%
Number of subjects: 33
Study: 29077615

Group type: EXPERIMENTAL
Intervention: Epinephrine 200 µg (high-dose group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Epinephrine 100 µg (low-dose group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No epinephrine (NE group)
Number of subjects: 68
Study: 27837602

Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention administered by lay health workers (5 weekly 90-minute sessions)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention
Number of subjects: 346

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 346
Study: 25103138

Group type: EXPERIMENTAL
Intervention: Maximal isometric hip and thigh strength measurements after 1 week
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Leg extensor power measurements
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Functional performance measures (8-foot Up & Go, stair climbing, chair stand, 6-min walk)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Quadriceps strength measurements in healthy peers
Number of subjects: 122
Study: 22561390

Group type: EXPERIMENTAL
Intervention: Counselor Initiated (proactive) group, receiving 6 counseling sessions and an 8-week supply of NRT
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Self-Paced (reactive) group, receiving the same counseling sessions and a 2-week supply of NRT
Number of subjects: 1000
Study: 20486914

Group type: EXPERIMENTAL
Intervention: Dual immunosuppressive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower blood concentrations of calcineurin inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer time since transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valganciclovir/ganciclovir therapy with lower total intensity of immunosuppressive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate and tacrolimus therapy
Number of subjects: 0
Study: 18608978

Group type: EXPERIMENTAL
Intervention: Instruction set reminder for the Autobiographical Memory Test (AMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task's instruction set
Number of subjects: 0
Study: 15654774

Group type: COMPARATOR
Intervention: Esomeprazole, Omeprazole, Ranitidine, or Placebo (exact dosages and durations not specified)
Number of subjects: 2674
Study: 11916787

Group type: EXPERIMENTAL
Intervention: Lidocaine HCl 2% with epinephrine 1:100,000 via iontophoresis
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (same formulation without lidocaine) via iontophoresis
Number of subjects: 59
Study: 10216810

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily for 10 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily for 2 weeks, with the option to increase to 10 mg once daily if diastolic blood pressure exceeded 90 mmHg
Number of subjects: 115
Study: 8582497

Group type: EXPERIMENTAL
Intervention: sIL-2R in PTL and TL groups (n = 15 and n = 17 respectively)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: sCD8 in PTL and TL groups (n = 15 and n = 17 respectively)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: sCD8 in PTL subgroup with histological evidence of inflammation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of PTL and TL groups
Number of subjects: 15
Study: 2223679

Group type: EXPERIMENTAL
Intervention: Betamethasone (1.5 mg orally per day from day 259 to day 273, then 1 mg until delivery)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 28
Study: 496239

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyoscine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no anticholinergic premedication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 0
Study: 30608872

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (8000 mg·day‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29285889

Group type: EXPERIMENTAL
Intervention: Topical liposome incorporated clove oil 45%
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline solution (control)
Number of subjects: 60
Study: 27473571

Group type: EXPERIMENTAL
Intervention: Asthma self-management model provided by a pharmacist over 4 months
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Asthma self-management model
Number of subjects: 119
Study: 25227062

Group type: EXPERIMENTAL
Intervention: Comprehensive verticality analysis and web-based rehabilitation system with face-to-face sessions and home exercises
Number of subjects: 10
Study: 22169248

Group type: EXPERIMENTAL
Intervention: Davunetide (AL-108) 5 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Davunetide (AL-108) 30 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 20086201

Group type: EXPERIMENTAL
Intervention: Exercise only (EXO)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss (DIO)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Exercise and diet-induced weight loss combined (DEX)
Number of subjects: 79
Study: 17400675

Group type: EXPERIMENTAL
Intervention: Verbal Training (VT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 2Tone Trainer (2T)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Good Technique (GT)
Number of subjects: 107
Study: 15749218

Group type: EXPERIMENTAL
Intervention: Full-thickness skin graft from inner upper arm
Number of subjects: 62

Group type: COMPARATOR
Intervention: Split-skin graft
Number of subjects: 62
Study: 11889309

Group type: EXPERIMENTAL
Intervention: Inspired gas at body temperature and saturated
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inspired gas conditions of 30 degrees C, 30 mg/L; 34 degrees C, 38 mg/L; 37 degrees C, 44 mg/L; and 40 degrees C, 50 mg/L
Number of subjects: 10
Study: 10080336

Group type: EXPERIMENTAL
Intervention: IFN-alpha (1 x 10(6) IU per dose)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 5-FU (5 mg per dose)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Alternating IFN-alpha and 5-FU (BOTH)
Number of subjects: 57
Study: 8547212

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 1731

Group type: COMPARATOR
Intervention: No Digoxin
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Digoxin in heart failure patients
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Digoxin in non-heart failure patients
Number of subjects: 1731
Study: 2024225

Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanate potassium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamicin and clindamycin
Number of subjects: 0
Study: 7171140

Group type: EXPERIMENTAL
Intervention: Electropharmaceutical anesthesia (EPA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Neuroleptanalgesia (NLA)
Number of subjects: 17
Study: 31992379

Group type: EXPERIMENTAL
Intervention: Patients with depressive disorders
Number of subjects: 192685

Group type: COMPARATOR
Intervention: Patients without depression
Number of subjects: 192685
Study: 30472318

Group type: EXPERIMENTAL
Intervention: FAmily‐CEntered (FACE) ACP intervention (two sessions including goals of care conversation and Five Wishes advance directive)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Healthy living control (conversations about developmental/relationship history and nutrition)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: FAmily‐CEntered (FACE) ACP intervention among African-Americans
Number of subjects: 233
Study: 27805791

Group type: EXPERIMENTAL
Intervention: Collagen mesh‐assisted closure
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional abdominal wound closure
Number of subjects: 58
Study: 25576879

Group type: EXPERIMENTAL
Intervention: Oral salmon calcitonin treatment for 2 years
Number of subjects: 2206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2206
Study: 25252721

Group type: EXPERIMENTAL
Intervention: Compression depth >38 mm
Number of subjects: 9136

Group type: EXPERIMENTAL
Intervention: Compression depth increment of 5 mm
Number of subjects: 9136

Group type: EXPERIMENTAL
Intervention: Percentage of minutes in depth range (10% change)
Number of subjects: 9136

Group type: EXPERIMENTAL
Intervention: Compression depth range 40.3 to 55.3 mm
Number of subjects: 9136
Study: 22322513

Group type: EXPERIMENTAL
Intervention: Scaling, root planning, and systemic administration of doxycycline
Number of subjects: 53

Group type: COMPARATOR
Intervention: Scaling and root planning
Number of subjects: 53
Study: 19804842

Group type: EXPERIMENTAL
Intervention: Sequential therapy (PPI, amoxicillin followed by PPI, clarithromycin, and imidazole agent)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (PPI, amoxicillin, clarithromycin, and imidazole agent)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Concomitant therapy
Number of subjects: 232
Study: 17626987

Group type: EXPERIMENTAL
Intervention: Crystacide (hydrogen peroxide cream) applied onto the skin for 10 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (treated without Crystacide)
Number of subjects: 32
Study: 16131287

Group type: EXPERIMENTAL
Intervention: Lavandula augustifolia (lavender)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sweet almond oil (placebo/control)
Number of subjects: 10
Study: 12395437

Group type: EXPERIMENTAL
Intervention: Renal protection with mannitol (0.3 g/kg) before aortic cross-clamping (ACC) and furosemide (20-40 mg) or dopamine (1-3 micrograms/kg/min) until the end of surgery.
Number of subjects: 80

Group type: COMPARATOR
Intervention: No renal protection (group A).
Number of subjects: 80
Study: 10091344

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (0.2%)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (500 mg/12 h)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (0.5%)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin plus 0.2% topical solution
Number of subjects: 125

Group type: COMPARATOR
Intervention: Topical polymyxin and neomycin
Number of subjects: 125
Study: 7748985

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg/kg ideal weight/h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 14
Study: 2148224

Group type: EXPERIMENTAL
Intervention: isradipine 1 mg i.v. (5 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: isradipine 5 mg solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: isradipine 5 mg tablet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: isradipine 10 mg sustained release
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 6809321

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ad libitum feeding
Number of subjects: 45
Study: 31732133

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus conventional treatment
Number of subjects: 245

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 245
Study: 30963552

Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric carboxymaltose)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Oral iron (ferrous sulphate)
Number of subjects: 116
Study: 28583700

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 240
Study: 26022239

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy and ASCT
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no high-dose cytarabine)
Number of subjects: 135
Study: 24224992

Group type: EXPERIMENTAL
Intervention: Supplementary otoscopy training including didactic otoscopy lectures and clinical training using manikin ears
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no supplementary training initially)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Experimental and control groups
Number of subjects: 32
Study: 21222604

Group type: EXPERIMENTAL
Intervention: EHT0202 (40 or 80 mg bid)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: EHT0202
Number of subjects: 159
Study: 19573497

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 30 mg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Caffeine 300 mg/d
Number of subjects: 24
Study: 17550958

Group type: EXPERIMENTAL
Intervention: Ghrelin (50 microg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17169762

Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 51
Study: 15298795

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (25 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 10742314

Group type: EXPERIMENTAL
Intervention: Infection control intervention (training of child care staff about transmission of infection and handwashing)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Infection control intervention (with high compliance to handwashing)
Number of subjects: 311
Study: 9398875

Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg bid plus amoxicillin, 1 gm tid
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg tid plus amoxicillin, 1 gm tid
Number of subjects: 262

Group type: COMPARATOR
Intervention: Lansoprazole, 30 mg tid alone
Number of subjects: 262

Group type: COMPARATOR
Intervention: Amoxicillin, 1 gm tid alone
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg bid plus amoxicillin
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg tid plus amoxicillin
Number of subjects: 262
Study: 1572111

Group type: EXPERIMENTAL
Intervention: Probenecid (1000 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Probenecid (2000 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Furosemide (0.5 mg/kg intravenously)
Number of subjects: 20
Study: 4048886

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (0.1 mg/kg/min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 25
Study: 31266353

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28207540

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 25 mg mifepristone
Number of subjects: 501

Group type: COMPARATOR
Intervention: 3.75 mg enantone
Number of subjects: 501
Study: 26390335

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy for insomnia (MBTI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-monitoring
Number of subjects: 0
Study: 23849965

Group type: EXPERIMENTAL
Intervention: Discharge heart rate 60-69 bpm
Number of subjects: 2029

Group type: EXPERIMENTAL
Intervention: Discharge heart rate 70-79 bpm
Number of subjects: 2029

Group type: EXPERIMENTAL
Intervention: Discharge heart rate 80-89 bpm
Number of subjects: 2029

Group type: EXPERIMENTAL
Intervention: Discharge heart rate >90 bpm
Number of subjects: 2029

Group type: EXPERIMENTAL
Intervention: Discharge heart rate <60 bpm
Number of subjects: 2029
Study: 21730029

Group type: EXPERIMENTAL
Intervention: Postexercise protein feeding (PTN: 0.4, 1.2, 0.2 g/kg protein, carbohydrate, and fat respectively)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Postexercise protein feeding (PTN)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate and fat (CON: 1.6, 0.2 g/kg)
Number of subjects: 8
Study: 17895513

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 25
Study: 17349094

Group type: COMPARATOR
Intervention: Regular Weight Watchers POINTS programme
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Revised programme encouraging low GI foods
Number of subjects: 96
Study: 14625735

Group type: EXPERIMENTAL
Intervention: Training in three other simulators with different visual-spatial components
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no training in other simulators)
Number of subjects: 28
Study: 11146518

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat stenting
Number of subjects: 0
Study: 9135193

Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intrathecal saline placebo
Number of subjects: 60